Eisai and Biogen Idec have
entered into a collaboration to
develop and commercialise two
of Eisai’s clinical candidates for
Alzheimer’s Disease (AD).
According to RTTNews.com, the
agreement also provides Eisai
with an option to jointly develop
and commercialise two of Biogen
Idec’s candidates for AD - the
anti-amyloid beta (Aβ) antibody
BIIB037 and an anti-tau monoclonal
antibody.
These candidates have the
potential to reduce Aβ plaques
that form in the brains of patients
with AD and to stop the formation
of new plaques, thus improving
symptoms and suppressing disease
progression.
Eisai, the original manufacturer of
donepezil (Aricept), a market leader
in AD therapy, will serve as the
operational and regulatory lead in
the co-development of E2609 and
BAN2401 and will pursue marketing
authorisations for both compounds
worldwide.The above article was sent to subscribers in Pharmacy Daily's issue from 07 Mar 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Mar 14
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.